# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 81-90 of 563 results.
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Status: Not yet recruiting
Last Changed: Jul 02, 2020
First Received: Apr 24, 2020
Disease(s): B-Cell Non-Hodgkin Lymphoma
Intervention(s): Anakinra, Axicabtagene Ciloleucel
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Status: Recruiting
Last Changed: Mar 17, 2020
First Received: Feb 12, 2019
Disease(s): Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
Intervention(s): Rituximab, Etoposide, Vincristine, Doxorubicin, Dexamethasone, Cyclophosphamide, Lenalidomide, Cisplatin, Cytarabine
Locations: Hunan Cancer Hospital, Changsha, Hunan, China
the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
the First Affiliated Hospital of Jilin University, Changchun, Jilin, China
the Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Qingdao Central Hospital, Qingdao, Shandong, China
... and 2 other locations.
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
Status: Recruiting
Last Changed: Jan 07, 2020
First Received: Mar 27, 2019
Disease(s): Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Intervention(s): Selicrelumab, Atezolizumab
Locations: APHP - Hôpital Henri Mondor, Créteil, France
CHU de Montpellier, Montpellier, France
Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, Pierre-Bénite, France
CHU de Rennes - Hôpital Pontchaillou, Rennes, France
Institut Gustave Roussy, Villejuif, France
... and 1 other locations.
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
Status: Not yet recruiting
Last Changed: Feb 28, 2020
First Received: Feb 28, 2020
Disease(s): B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
Intervention(s): Anti-CD19 CAR-T Cells Injection
Locations: Kunming Yan'an Hospital, Kunming, Yunnan, China
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
Status: Recruiting
Last Changed: Feb 26, 2019
First Received: Feb 26, 2019
Disease(s): B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
Intervention(s): Anti-CD19 CAR-T Cells Injection
Locations: Kunming Yan'an Hospital, Oncology Department, Kunming, Yunnan, China
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Status: Recruiting
Last Changed: Jun 04, 2020
First Received: May 06, 2019
Disease(s): Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Intervention(s): Abexinostat, Ibrutinib
Locations: Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
... and 3 other locations.
An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)
Status: Recruiting
Last Changed: Jul 17, 2018
First Received: Feb 03, 2015
Disease(s): B-cell Lymphoma
Locations: Severance Hospital, Seoul, Korea, Republic of
A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 08, 2019
First Received: Oct 12, 2017
Disease(s): B Cell Lymphoma
Intervention(s): Varlilumab
Locations: The Christie NHS Foundation Trust, Manchester, United Kingdom
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Plymouth Hospitals NHS Trust, Plymouth, United Kingdom
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
Status: Recruiting
Last Changed: Jul 08, 2019
First Received: Jun 14, 2019
Disease(s): Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Intervention(s): blood sample
Locations: University Hospital Limoges, Limoges, France
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Status: Recruiting
Last Changed: Apr 22, 2020
First Received: Sep 14, 2016
Disease(s): Chronic Lymphocytic Leukemia, B-Cell Lymphoma
Intervention(s): DTRMWXHS-12, DTRM-505, DTRM-555
Locations: Mayo Clinic, Phoenix, Arizona, United States
Yale Cancer Center, New Haven, Connecticut, United States
Mayo Clinic, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
Duke University Medical Center, Durham, North Carolina, United States
... and 2 other locations.